Tagged Articles

Bayer 288 articles

Xarelto sales expected to boost J&J’s bottom line in 2017


Consumer health care products and medical devices generate billions of dollars for Johnson & Johnson. Its pharmaceutical offerings are expected to drive the company’s growth in the year ahead, with its blockbuster blood thinner Xarelto among the leaders of the pack, according to analyst Todd Campbell, owner of E.B. Capital Markets, LLC. Xarelto, manufactured by J&J unit Janssen Pharmaceuticals and Bayer, was approved in 2011 as the second in a new class of blood thinners competing with the long-used warfarin for the prevention of strokes in patients with atrial fibrillation. The medication is also used to treat deep vein thrombosis ... Read More

Xarelto linked to more GI bleeds than Pradaxa, Eliquis


A study published in the journal Gastroenterology pitting three newer blood thinners – Pradaxa, Xarelto and Eliquis – found that patients taking Xarelto were at a 20 percent greater risk of gastrointestinal bleeds compared to patients taking Pradaxa or Eliquis. The three blood thinners are in a new class of anticoagulants called Factor Xa inhibitors. They are used to prevent strokes in patients with the common heart rhythm condition called atrial fibrillation. They are also used to treat various blood clot-related conditions. Pradaxa contains the active ingredient dabigatran; Xarelto contains rivaroxaban; and Eliquis contains apixaban. The retrospective study used data ... Read More

New York, Louisiana considered for Eliquis MDL


Bristol-Myers Squibb Co. and Pfizer Inc., are asking the U.S. Judicial Panel on Multidistrict Litigation to centralize the 34 lawsuits alleging the companies’ blood thinner Eliquis caused bleeding injuries in the Southern District of New York, where both companies are headquartered. Doing so would improve efficiency and consistency, the drug companies argued. All but two of the plaintiffs suing Bristol-Myers Squibb and Pfizer support consolidation in a multidistrict litigation. Where to centralize the cases is the issue. New York leads in the number of cases with 16. The Eastern District of Louisiana is a distant second with four cases. But ... Read More

Pennsylvania Xarelto mass tort grew 121 percent in 2016


The number of Xarelto cases in a mass tort program in Philadelphia’s Complex Litigation Center jumped a startling 121 percent in 2016 with the addition of 664 new cases. The lawsuits claim that Xarelto makers, Johnson & Johnson, Janssen Pharmaceuticals and Bayer, did not adequately warn doctors or patients about bleeding side effects associated with the drug. They also allege the drug companies erred by marketing the drug when there was no antidote on the market to reverse the bleeding effects of the drug in the event of a bleeding emergency. Xarelto side effects include gastrointestinal bleeds, brain bleeds and ... Read More

New Xarelto lawsuit claims blood thinner caused bleeding death


The children of a Louisiana woman who allegedly bled to death after taking the blood thinner Xarelto joined a massive multidistrict litigation (MDL) accusing Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer of failing to warn of risks associated with the drug. Terrie Toups, Duane Rochelle and Patty Buras, children of Florence Bourgeois, filed their lawsuit in Louisiana federal court, where U.S. District Judge Eldon Fallon is overseeing the near-14,000 lawsuits in the multidistrict litigation against the drug companies involving bleeding risks. Xarelto, known chemically as rivaroxaban, was approved by the Food and Drug Administration (FDA) in 2011 and ... Read More

First Xarelto bleeding risks trial scheduled for March 2017


The first trial in a massive multidistrict litigation of nearly 14,000 cases involving bleeding risks allegedly caused by the blood thinner Xarelto is scheduled for March, with other trials, each serving as bellwethers, slated for April and May. The first case to be tried involves that of Joseph Boudreaux, who claims he began taking Xarelto in January 2014 as a treatment for his heart condition called atrial fibrillation. About a month later, he was hospitalized for internal bleeding, resulting in multiple blood transfusions. Like the thousands of other lawsuits, Boudreaux claims that Xarelto’s makers, Johnson & Johnson’s Janssen Pharmaceuticals and ... Read More

Eliquis sales poised to top Xarelto in blood thinner market


Bristol-Myers Squibb (BMS) and Pfizer’s blood thinner Eliquis is poised to edge ahead of Johnson & Johnson’s Janssen Pharmaceuticals and Bayer’s Xarelto in 2017 and become the market leader. BMS CEO Giovanni Caforio added, “We think we are relatively close to achieving that.” Eliquis has already nabbed the top spot in the institutional setting, such as in hospitals and cardiologists’ offices, beating out long-used warfarin, and is making ground among primary care physicians. “We are beginning to see very, very strong momentum,” Caforio added. Xarelto and Eliquis were approved by the Food and Drug Administration (FDA) in 2011 and 2012, ... Read More

Bayer recalls administration sets used with infusion system


Bayer is recalling more than 86,000 Source Administration Sets used with the Medrad Intego PET Infusion System because they may produce a particulate matter in the medicine vials created when the tip of the needle pushes through the rubber top of the vial. If this occurs, the particulate matter could enter into the patient and cause serious adverse health consequences including infection, tissue damage, and death. Medrad Intego PET Infusion Systems control and deliver medications from a chamber to patients through a needle inserted into a vein during nuclear medicine procedures. These procedures are used to diagnose and treat diseases ... Read More

Blood thinner sales expected to grow through 2021


Sales of blood thinners are expected to surge through 2021, thanks in part to a popular novel new class of anticoagulants, according to an analysis by Persistence Market Research. Blood thinners are life-saving medications that are used to prevent or treat blood clots in the blood vessels, which can block blood circulation leading to serious health consequences. They are commonly used to treat deep vein thrombosis (blood clots in the deep veins, often in the legs), pulmonary embolism (blood clots in the lungs), atrial fibrillation (an irregular heart rhythm that can cause blood clots to develop in the chambers of ... Read More

Xarelto makers face 15,000 bleeding risks lawsuits


Johnson & Johnson, its subsidiary Janssen Pharmaceuticals, and Bayer will come into the New Year gearing up for a series of trials alleging life-threatening bleeding risks with their blood thinner Xarelto. The lawsuits claim the drug companies did not adequately warn consumers that the drug could cause gastrointestinal bleeds, brain hemorrhages and bleeding deaths, and that the drug was poorly designed and marketed because there is no antidote to reverse the bleeding effects of Xarelto. Xarelto was approved by the Food and Drug Administration (FDA) in 2011, and is now the top-selling blood thinner in a new class of drugs called ... Read More